Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1963 1
1965 1
1966 1
1981 1
1986 2
1989 1
1990 1
1991 3
1993 3
1994 4
1995 3
1996 3
1997 4
1998 5
1999 10
2000 8
2001 14
2002 11
2003 10
2004 14
2005 16
2006 22
2007 25
2008 24
2009 22
2010 28
2011 41
2012 50
2013 50
2014 43
2015 69
2016 106
2017 80
2018 99
2019 102
2020 103
2021 132
2022 163
2023 151
2024 53

Text availability

Article attribute

Article type

Publication date

Search Results

1,301 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.
Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y, Liu B, Niu L, Sun X, Yu X, Wang Y, Chang Q, Gong T, Guan X, Hu T, Qian T, Xu B, Ma F, Zhang Z, Liu Z. Zhang Y, et al. Among authors: mo h. Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8. doi: 10.1016/j.ccell.2021.09.010. Epub 2021 Oct 14. Cancer Cell. 2021. PMID: 34653365 Free article.
Tumor buster - where will the CAR-T cell therapy 'missile' go?
Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F, Zhang L, Yi Z, Long L, Yan L, Wang Z, Zhang N, Luo P, Zhang J, Liu Z, Ye W, Liu Z, Cheng Q. Qu C, et al. Among authors: mo h. Mol Cancer. 2022 Oct 19;21(1):201. doi: 10.1186/s12943-022-01669-8. Mol Cancer. 2022. PMID: 36261831 Free PMC article. Review.
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Xie FY, Sun Y, Ma J, Tang LL. Zhang Y, et al. Among authors: mo hy. J Clin Oncol. 2022 Aug 1;40(22):2420-2425. doi: 10.1200/JCO.22.00327. Epub 2022 Jun 16. J Clin Oncol. 2022. PMID: 35709465 Clinical Trial.
1,301 results